# EDGAR Filing Document

**Accession Number:** 0001711786
**File Stem:** 0000000000-23-000074
**Filing Date:** 2023-1
**Character Count:** 2778
**Document Hash:** 334f8eab64c1406adee712187d1ce25a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000074.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0000000000-23-000074

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230104

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hoth Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001711786
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821553794
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 1 ROCKEFELLER PLAZA, SUITE 1039
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10020
- **BUSINESS PHONE:** 551-578-2261

**MAIL ADDRESS:**
- **STREET 1:** 1 ROCKEFELLER PLAZA, SUITE 1039
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10020

## Text-Extract

```

United States securities and exchange commission logo

                     January 4, 2023

       David Briones
       Chief Financial Officer
       Hoth Therapeutics, Inc.
       1 Rockefeller Plaza, Suite 1039
       New York, NY 10020

                                                        Re: Hoth Therapeutics,
Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2021
                                                            Filed March 30,
2022
                                                            File No. 001-38803

       Dear David Briones:

              We have completed our review of your filing. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                     Sincerely,

                     Division of Corporation Finance

                     Office of Life Sciences
       cc:                                              Haley Springer

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 4, 2023

David Briones
Chief Financial Officer
Hoth Therapeutics, Inc.
1 Rockefeller Plaza, Suite 1039
New York, NY 10020

**Re: Hoth Therapeutics, Inc.**
**Form 10-K for the Fiscal Year Ended December 31, 2021**
**Filed March 30, 2022**
**File No. 001-38803**

Dear David Briones:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Haley Springer